| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nobuaki Egashira, Ryoko Okuno, Michihiko Matsushita, Moe Abe, Kenichi Mishima, Katsunori Iwasaki, Ryoji Nishimura, Ryozo Oishi, Michihiro Fujiwar. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. European journal of pharmacology. vol 592. issue 1-3. 2008-10-24. PMID:18644366. |
in the present study, we examined the effect of aripiprazole on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder, and compared this with the effects of other atypical antipsychotics such as olanzapine and quetiapine. |
2008-10-24 |
2023-08-12 |
mouse |
| Paul E Croarkin, Graham J Emslie, Taryn L Maye. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18572981. |
to retrospectively examine published cases of neuroleptic malignant syndrome (nms) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole). |
2008-09-09 |
2023-08-12 |
Not clear |
| Lefteris Lykouras, Emmanouil Rizos, Rossetos Gournelli. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 7. 2007-12-06. PMID:17614184. |
aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. |
2007-12-06 |
2023-08-12 |
Not clear |
| Gilbert J L'Italien, Daniel E Casey, Hong J Kan, William H Carson, Ronald N Marcu. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. The Journal of clinical psychiatry. vol 68. issue 10. 2007-11-19. PMID:17960964. |
we compared both the rate and incidence of metabolic syndrome among schizophrenia patients (dsm-iv criteria) treated with the atypical antipsychotics aripiprazole or olanzapine or placebo from 4 double-blind, randomized, controlled clinical trials. |
2007-11-19 |
2023-08-12 |
Not clear |
| Andreas Fellgiebel, Matthias J Müller, Christoph Hiemke, Peter Bartenstein, Matthias Schreckenberge. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 2. 2007-08-01. PMID:17455105. |
according to this case experience, further investigations should be undertaken to ascertain whether aripiprazole or other atypical antipsychotics with properties to improve impaired dopaminergic transmission in frontal brain regions could qualify for therapy of ftd. |
2007-08-01 |
2023-08-12 |
Not clear |
| Pierre Thoma. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17 Suppl 2. 2007-05-14. PMID:17336766. |
twenty-six weeks of aripiprazole treatment, assessed in 284 patients in the schizophrenia trial of aripiprazole (star) showed that aripiprazole had similar discontinuation rates to the atypical antipsychotics standard of care. |
2007-05-14 |
2023-08-12 |
Not clear |
| Terence A Ketter, Henry A Nasrallah, Andrea Fagiolin. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacology bulletin. vol 39. issue 1. 2007-04-03. PMID:17065977. |
the authors reviewed the literature on the efficacy of agents with the best clinical evidence supporting their use in bipolar disorder, including the mood stabilizers lithium, valproate, lamotrigine, and carbamazepine, as well as the atypical antipsychotics olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. |
2007-04-03 |
2023-08-12 |
Not clear |
| Prashant Gajwani, David E Kemp, David J Muzina, Guohua Xia, Keming Gao, Joseph R Calabres. Acute treatment of mania: an update on new medications. Current psychiatry reports. vol 8. issue 6. 2007-02-22. PMID:17094930. |
since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the fda for the management of acute mania. |
2007-02-22 |
2023-08-12 |
Not clear |
| Karen E Moeller, Theresa I Shireman, Barry I Lisko. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. The Journal of clinical psychiatry. vol 67. issue 12. 2007-01-09. PMID:17194273. |
relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. |
2007-01-09 |
2023-08-12 |
Not clear |
| Agnès L Auclair, Mark S Kleven, Joël Besnard, Ronan Depoortère, Adrian Newman-Tancred. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 9. 2006-09-28. PMID:16421514. |
the atypical antipsychotics, clozapine (40 mg/kg), nemonapride (0.01-2.5 mg/kg), ziprasidone (10 mg/kg), and aripiprazole (0.01 and 10 mg/kg), which all exhibit 5-ht1a agonist properties, reversed ppi deficits at some doses only, whereas the anti-dyskinetic agent sarizotan (0.16-10 mg/kg), an efficacious 5-ht1a agonist, did not. |
2006-09-28 |
2023-08-12 |
rat |
| Ricardo Alberto Moreno, Doris Hupfeld Moreno, Márcia Britto de Macedo Soares, Roberto Ratzk. [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 26 Suppl 3. 2005-10-26. PMID:15597138. |
the available literature on the use of anticonvulsants (valproate, carbamazepine, oxcarbazepine, lamotrigine, gabapentin, topiramate, clonazepam) and atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) for acute and prophylactic treatment of bipolar disorder was reviewed. |
2005-10-26 |
2023-08-12 |
Not clear |
| Steven A Seifert, Michael D Schwartz, Jerry D Thoma. Aripiprazole (abilify) overdose in a child. Clinical toxicology (Philadelphia, Pa.). vol 43. issue 3. 2005-06-02. PMID:15902794. |
aripiprazole, 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1h)-quinolinone, is an atypical antipsychotic medication inaugurating the newest class of atypical antipsychotics: the partial dopamine agonists. |
2005-06-02 |
2023-08-12 |
Not clear |
| Martha Sajatovic, Subramoniam Madhusoodanan, Nicoleta Coconce. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs & aging. vol 22. issue 1. 2005-05-13. PMID:15663348. |
olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole are atypical antipsychotics that have been approved by the us fda for the treatment of bipolar disorder; however, there are no published, controlled trials with atypical antipsychotics specific to mania in geriatric patients. |
2005-05-13 |
2023-08-12 |
Not clear |
| S M Stahl, M M Grad. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current medicinal chemistry. vol 11. issue 3. 2004-04-20. PMID:14965234. |
the atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms. |
2004-04-20 |
2023-08-12 |
Not clear |
| Paul J Goodnick, Jason M Jerr. Aripiprazole: profile on efficacy and safety. Expert opinion on pharmacotherapy. vol 3. issue 12. 2003-05-05. PMID:12472374. |
among the atypical antipsychotics, aripiprazole displays the lowest affinity for alpha(1)adrenergic (alpha(1)), histamine (h1) and muscarinic (m1) receptors. |
2003-05-05 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. |
2002-12-17 |
2023-08-12 |
Not clear |